Stay updated with breaking news from Total Sharp Score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In these phase 3 findings presented at ACR 2023, the safety and efficacy of this drug was proven in American College of Rheumatology-20 (ACR20), ACR50, and Disease Activity Score in 28 joints with Erythrocyte Sedimentation Rate responses.
A moderate agreement was noted between DAPSA and VLDA/MDA composite instruments among patients with PsA receiving tofacitinib.
First presentations from the BE OPTIMAL and BE COMPLETE studies evaluating bimekizumab in the treatment of adults with active psoriatic arthritis who were...
The FDA has approved Rinvoq (upadacitinib) for the treatment of active psoriatic arthritis.
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for...